114 related articles for article (PubMed ID: 10482004)
1. The SCID-hu xenogeneic transplantation model: complex but telling.
Boehncke WH
Arch Dermatol Res; 1999; 291(7-8):367-73. PubMed ID: 10482004
[TBL] [Abstract][Full Text] [Related]
2. The fate of human peripheral blood lymphocytes after transplantation into SCID mice.
Martino G; Anastasi J; Feng J; Mc Shan C; DeGroot L; Quintans J; Grimaldi LM
Eur J Immunol; 1993 May; 23(5):1023-8. PubMed ID: 8477797
[TBL] [Abstract][Full Text] [Related]
3. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection.
Briscoe DM; Dharnidharka VR; Isaacs C; Downing G; Prosky S; Shaw P; Parenteau NL; Hardin-Young J
Transplantation; 1999 Jun; 67(12):1590-9. PubMed ID: 10401767
[TBL] [Abstract][Full Text] [Related]
4. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes.
Sandhu JS; Gorczynski R; Shpitz B; Gallinger S; Nguyen HP; Hozumi N
Transplantation; 1995 Jul; 60(2):179-84. PubMed ID: 7624960
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic and xenogeneic vascular injury and protection.
Pober JS; Schechner JS; Murray AG; Sultan P; Kirkiles N; Tereb D; Wilson J; McNiff JM; Askenase PW; Tellides G; Lorber MI
Transplant Proc; 1998 Dec; 30(8):4168-9. PubMed ID: 9865336
[No Abstract] [Full Text] [Related]
6. [Psoriasis SCID-mouse model].
Pfeffer J; Kaufmann R; Boehncke WH
Hautarzt; 2006 Jul; 57(7):603-9. PubMed ID: 16028077
[TBL] [Abstract][Full Text] [Related]
7. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the human anti-pig cellular immune response using the Hu-scid mouse-porcine skin graft model.
Moss A; Fryer JP; Leventhal JR; Simone P; Chen S; Reinsmoen N; Matas AJ
Transplant Proc; 1994 Jun; 26(3):1209. PubMed ID: 8029889
[No Abstract] [Full Text] [Related]
9. Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells.
Gysemans C; Waer M; Laureys J; Depovere J; Pipeleers D; Bouillon R; Mathieu C
Clin Exp Immunol; 2000 Sep; 121(3):557-65. PubMed ID: 10971525
[TBL] [Abstract][Full Text] [Related]
10. Modeling human hematopoiesis in immunodeficient mice.
Lapidot T; Pflumio F; Dick JE
Lab Anim Sci; 1993 Apr; 43(2):147-50. PubMed ID: 8320962
[No Abstract] [Full Text] [Related]
11. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
12. Biliary duct lesions following xenogeneic liver and peripheral blood lymphocyte grafts in SCID mice.
Bestian JM; Janin A; Zenner I; Zelus D; Pruvot FR; Dessaint JP; Capron A
Transplant Proc; 1995 Apr; 27(2):1720. PubMed ID: 7725469
[No Abstract] [Full Text] [Related]
13. Survival of fetal skin grafts is prolonged on the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient mouse/skin allograft model.
Erdag G; Morgan JR
Transplantation; 2002 Feb; 73(4):519-28. PubMed ID: 11889422
[TBL] [Abstract][Full Text] [Related]
14. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
[TBL] [Abstract][Full Text] [Related]
15. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse.
McCune JM; Péault B; Streeter PR; Rabin L
Immunol Rev; 1991 Dec; 124():45-62. PubMed ID: 1804780
[TBL] [Abstract][Full Text] [Related]
17. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes.
Nonoyama S; Smith FO; Ochs HD
J Immunol; 1993 Oct; 151(7):3894-901. PubMed ID: 8376809
[TBL] [Abstract][Full Text] [Related]
18. Xenogeneic PBL-scid mice: their potential and current limitations.
Greenwood JD
Lab Anim Sci; 1993 Apr; 43(2):151-5. PubMed ID: 8320963
[TBL] [Abstract][Full Text] [Related]
19. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications.
Flavell DJ
Hematol Oncol; 1996 Jun; 14(2):67-82. PubMed ID: 8876636
[No Abstract] [Full Text] [Related]
20. Human immunoglobulins produced in hu-PBL-SCID mice are polyclonal early after xenotransplantation.
Tissot JD; Schneider P; Schapira M; Duchosal MA
Cell Immunol; 1996 Feb; 167(2):241-8. PubMed ID: 8603433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
